Angela’s Story

image angela patient
Angela was in her early 20s when she came to Dante Labs desperate for help in diagnosing her strange symptoms. Dante Labs sequenced Angela's whole genome ultimately diagnosing Angela with a rare disease, bringing her out of a years long diagnostic odyssey.

Angela was in her early 20s when she came to Dante Labs desperate for help in diagnosing her strange symptoms. Dante Labs sequenced Angela’s whole genome ultimately diagnosing Angela with a rare disease, bringing her out of a years long diagnostic odyssey.

While grateful for finally having a diagnosis, unfortunately, there were no drugs or treatments for Angela’s condition. Dante Labs came together as a team, recognizing the Company’s responsibility to Angela, its capabilities in R&D technology, and the strength of its platform to expand into drug discovery and development.

The Company was able to launch Dante’s Discovery program with a rare disease EMA orphan drug application now in the late stages of its non-regulatory pre-clinical phase to treat Angela’s rare disease.

With a pipeline of six drug discovery programs, Dante Labs is working to deliver genomic solutions from diagnosis to treatment to prevention, so people like Angela can lead healthier lives.

Share This Post

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

%d bloggers like this: